Analysts at Craig Hallum began coverage on shares of Aspen Aerogels Inc. (NYSE:ASPN) in a report issued on Tuesday. The firm set a “buy” rating and a $10.00 price target on the stock. Craig Hallum’s price target points to a potential upside of 90.84% from the stock’s previous close.

Several other research firms have also recently weighed in on ASPN. Canaccord Genuity reiterated a “buy” rating and issued a $8.50 price target on shares of Aspen Aerogels in a report on Thursday, August 4th. Zacks Investment Research cut shares of Aspen Aerogels from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. JPMorgan Chase & Co. reduced their target price on shares of Aspen Aerogels from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Friday, August 5th. Finally, Citigroup Inc. reduced their target price on shares of Aspen Aerogels from $6.50 to $6.00 and set a “buy” rating for the company in a report on Thursday, July 7th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $7.70.

Aspen Aerogels (NYSE:ASPN) opened at 5.24 on Tuesday. Aspen Aerogels has a 12-month low of $3.38 and a 12-month high of $8.87. The stock’s 50 day moving average is $4.89 and its 200 day moving average is $4.61. The company’s market cap is $107.85 million.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The company earned $27.70 million during the quarter, compared to analysts’ expectations of $30.99 million. Aspen Aerogels had a negative net margin of 3.14% and a negative return on equity of 3.35%. During the same quarter in the prior year, the company earned ($0.12) earnings per share. On average, equities analysts forecast that Aspen Aerogels will post ($0.31) earnings per share for the current year.

In other news, Director William P. Noglows purchased 20,000 shares of the business’s stock in a transaction on Wednesday, August 24th. The stock was purchased at an average price of $4.98 per share, for a total transaction of $99,600.00. Following the completion of the purchase, the director now directly owns 46,178 shares in the company, valued at approximately $229,966.44. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark L. Noetzel purchased 13,576 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was purchased at an average price of $4.74 per share, with a total value of $64,350.24. Following the purchase, the director now owns 36,178 shares of the company’s stock, valued at $171,483.72. The disclosure for this purchase can be found here. 14.70% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Firsthand Capital Management Inc. boosted its stake in shares of Aspen Aerogels by 16.7% in the second quarter. Firsthand Capital Management Inc. now owns 35,000 shares of the company’s stock worth $174,000 after buying an additional 5,000 shares in the last quarter. Bridgeway Capital Management Inc. boosted its stake in shares of Aspen Aerogels by 24.6% in the second quarter. Bridgeway Capital Management Inc. now owns 252,130 shares of the company’s stock worth $1,253,000 after buying an additional 49,700 shares in the last quarter. Spark Investment Management LLC boosted its stake in shares of Aspen Aerogels by 295.0% in the second quarter. Spark Investment Management LLC now owns 55,700 shares of the company’s stock worth $276,000 after buying an additional 41,600 shares in the last quarter. Wall Street Associates boosted its stake in shares of Aspen Aerogels by 28.8% in the second quarter. Wall Street Associates now owns 566,200 shares of the company’s stock worth $2,814,000 after buying an additional 126,774 shares in the last quarter. Finally, Reservoir Operations L.P. boosted its stake in shares of Aspen Aerogels by 0.6% in the second quarter. Reservoir Operations L.P. now owns 2,916,103 shares of the company’s stock worth $14,493,000 after buying an additional 18,451 shares in the last quarter. Hedge funds and other institutional investors own 76.10% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Receive News & Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.